View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 23, 2021

Bavarian Nordic starts Phase II Covid-19 booster vaccine study

The trial will enrol a total of up to 210 healthy adults in Germany who will receive a single or two vaccine doses.

Bavarian Nordic has launched a Phase II clinical trial to evaluate its Covid-19 vaccine candidate, ABNCoV2, as a booster for people with prior SARS-CoV-2 infection or vaccination.

Initially developed by AdaptVac using its capsid virus-like particle (cVLP) technology, ABNCoV2 was licensed by Bavarian Nordic for worldwide commercialisation and clinical development.

Sponsored by Bavarian Nordic, the new Phase II trial is designed to enrol up to 210 healthy adults.

A group of 150 seropositive, which includes existing immunity from previous illness or a complete vaccination with approved Covid-19 vaccines, participants will be given one 100μg dose of ABNCoV2.

In these subjects, the aim is to bolster existing SARS-CoV-2 neutralising antibody levels.

Two 100μg doses of the vaccine will be administered 28 days apart in the second group of up to 60 seronegative volunteers without previous infection or inoculation.

This group is intended to assess neutralising antibody levels from when the vaccine is given as a prime booster.

The trial’s primary endpoint is SARS-CoV-2 neutralising antibody titres at two weeks following the last vaccination, which is following the second inoculation in initially seronegative participants and after the single booster dose in seropositive participants.

Additional study goals are the vaccine’s safety and neutralising antibody titres against variant strains that are circulating during analysis at two weeks from the last inoculation, among others.

Preliminary data from the trial are anticipated in the fourth quarter of this year.

Participants in the first group will continue the trial for up to two years to analyse the immune response durability from the booster vaccine dose.

Bavarian Nordic president and CEO Paul Chaplin said: “There is a growing expectation that booster vaccinations will be required to manage the pandemic and to broaden the protection against emerging variants and we remain committed to the development of ABNCoV2, as we believe it has the potential to fulfil these requirements.”

Earlier this month, the company announced positive preliminary data from the first-in-human Phase I/II dose-escalation trial of ABNCoV2.

The company is currently also working to conduct a Phase III trial of the vaccine next year.

Related Companies

Free Report

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy